Foresee Pharmaceuticals Co Ltd (TWO:6576) — Market Cap & Net Worth
Market Cap & Net Worth: Foresee Pharmaceuticals Co Ltd (6576)
Foresee Pharmaceuticals Co Ltd (TWO:6576) has a market capitalization of $391.65 Million (NT$12.43 Billion) as of June 18, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #13690 globally and #559 in its home market, demonstrating a 1.41% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Foresee Pharmaceuticals Co Ltd's stock price NT$79.00 by its total outstanding shares 157357666 (157.36 Million). Review Foresee Pharmaceuticals Co Ltd total liabilities to assess the company's total debt and financial obligations.
Foresee Pharmaceuticals Co Ltd Market Cap History: 2016 to 2026
Foresee Pharmaceuticals Co Ltd's market capitalization history from 2016 to 2026. Data shows change from $328.30 Million to $391.65 Million (-2.71% CAGR).
Foresee Pharmaceuticals Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Foresee Pharmaceuticals Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.92x
Foresee Pharmaceuticals Co Ltd's market cap is 0.92 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $309.46 Million | $23.73 Million | -$443.49 Million | 13.04x | N/A |
| 2018 | $269.24 Million | $26.04 Million | -$551.51 Million | 10.34x | N/A |
| 2019 | $281.46 Million | $75.20 Million | -$487.21 Million | 3.74x | N/A |
| 2020 | $439.32 Million | $230.44 Million | -$510.71 Million | 1.91x | N/A |
| 2021 | $585.92 Million | $226.03 Million | -$569.27 Million | 2.59x | N/A |
| 2022 | $448.14 Million | $301.51 Million | -$472.64 Million | 1.49x | N/A |
| 2023 | $476.92 Million | $195.04 Million | -$1.04 Billion | 2.45x | N/A |
| 2024 | $384.22 Million | $418.69 Million | -$1.08 Billion | 0.92x | N/A |
Competitor Companies of 6576 by Market Capitalization
Companies near Foresee Pharmaceuticals Co Ltd in the global market cap rankings as of June 18, 2026.
Key companies related to Foresee Pharmaceuticals Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #513 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #561 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #624 globally with a market cap of $44.20 Billion USD ( CN¥302.05 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #513 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #561 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.22 |
| #624 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $44.20 Billion | CN¥47.35 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.60 |
Foresee Pharmaceuticals Co Ltd Historical Marketcap From 2016 to 2026
Between 2016 and today, Foresee Pharmaceuticals Co Ltd's market cap moved from $328.30 Million to $ 391.65 Million, with a yearly change of -2.71%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$391.65 Million | -1.99% |
| 2025 | NT$399.58 Million | +4.00% |
| 2024 | NT$384.22 Million | -19.44% |
| 2023 | NT$476.92 Million | +6.42% |
| 2022 | NT$448.14 Million | -23.51% |
| 2021 | NT$585.92 Million | +33.37% |
| 2020 | NT$439.32 Million | +56.08% |
| 2019 | NT$281.46 Million | +4.54% |
| 2018 | NT$269.24 Million | -13.00% |
| 2017 | NT$309.46 Million | -5.74% |
| 2016 | NT$328.30 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Foresee Pharmaceuticals Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $391.65 Million USD |
| MoneyControl | $391.65 Million USD |
| MarketWatch | $391.65 Million USD |
| marketcap.company | $391.65 Million USD |
| Reuters | $391.65 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Foresee Pharmaceuticals Co Ltd
Foresee Pharmaceuticals Co., Ltd. operates as biopharmaceutical company in the United States, China, and Europe. The company's stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release … Read more